文献速递胃肠动力与功能性疾病

随机临床试验:棕榈酰乙醇酰胺与虎杖苷膳食补充对肠易激综合征的镇痛作用

Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2017-02-06

这项先导性、12周、随机、双盲、安慰剂对照、多中心研究在54例肠易激综合征(IBS)患者和12名健康对照中评估棕榈酰乙醇酰胺/虎杖苷200 mg/20 mg每日两次对低度免疫激活、内源性大麻素系统及症状的影响。IBS患者基线黏膜肥大细胞计数高于对照、油酰乙醇酰胺降低、大麻素受体2表达升高;治疗未显著改变包括肥大细胞计数在内的生物学特征,但与安慰剂相比腹部疼痛严重度明显改善。作者认为该补充剂是IBS疼痛管理有前景的天然途径,需进一步研究阐明机制。

要点

  • 与对照相比,IBS患者黏膜肥大细胞计数升高(3.2±1.3 vs 5.3±2.7%,P=0.013)。
  • 棕榈酰乙醇酰胺/虎杖苷未显著改变IBS生物学特征,包括肥大细胞计数。
  • 与安慰剂相比,该补充剂明显改善腹部疼痛严重度(P<0.05)。

核心结论

  • 棕榈酰乙醇酰胺/虎杖苷对IBS患者腹部疼痛有明显作用,作者认为这是该病疼痛管理有前景的天然途径。
  • 作者指出需进一步研究以阐明棕榈酰乙醇酰胺/虎杖苷在IBS中的作用机制。

研究设计与样本

  • 先导性、12周、随机、双盲、安慰剂对照、多中心研究,比较棕榈酰乙醇酰胺/虎杖苷200 mg/20 mg每日两次与安慰剂。
  • 共纳入54例IBS患者和12名健康对照,来自五个欧洲中心。
  • 筛查访视和研究结束时取活检样本,用免疫组化、酶联免疫分析、液相色谱和蛋白质印迹分析。

主要发现

  • 与对照相比,IBS患者黏膜肥大细胞计数升高(3.2±1.3 vs 5.3±2.7%,P=0.013)。
  • 与对照相比,IBS患者脂肪酸酰胺油酰乙醇酰胺降低(12.7±9.8 vs 45.8±55.6 pmol/mg,P=0.002)。
  • 与对照相比,IBS患者大麻素受体2表达升高(0.7±0.1 vs 1.0±0.8,P=0.012)。
  • 治疗未显著改变IBS生物学特征,包括肥大细胞计数。
  • 与安慰剂相比,棕榈酰乙醇酰胺/虎杖苷明显改善腹部疼痛严重度(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文称本研究为先导性研究。
  • 作者在结论中指出需进一步研究以阐明棕榈酰乙醇酰胺/虎杖苷在IBS中的作用机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intestinal immune activation is involved in irritable bowel syndrome (IBS) pathophysiology. While most dietary approaches in IBS involve food avoidance, there are fewer indications on food supplementation. Palmithoylethanolamide, structurally related to the endocannabinoid anandamide, and polydatin are dietary compounds which act synergistically to reduce mast cell activation. AIM: To assess the effect on mast cell count and the efficacy of palmithoylethanolamide/polydatin in patients with IBS. METHODS: We conducted a pilot, 12-week, randomised, double-blind, placebo-controlled, multicentre study assessing the effect of palmithoylethanolamide/polydatin 200 mg/20 mg or placebo b.d. on low-grade immune activation, endocannabinoid system and symptoms in IBS patients. Biopsy samples, obtained at screening visit and at the end of the study, were analysed by immunohistochemistry, enzyme-linked immunoassay, liquid chromatography and Western blot. RESULTS: A total of 54 patients with IBS and 12 healthy controls were enrolled from five European centres. Compared with controls, IBS patients showed higher mucosal mast cell counts (3.2 ± 1.3 vs. 5.3 ± 2.7%, P = 0.013), reduced fatty acid amide oleoylethanolamide (12.7 ± 9.8 vs. 45.8 ± 55.6 pmol/mg, P = 0.002) and increased expression of cannabinoid receptor 2 (0.7 ± 0.1 vs. 1.0 ± 0.8, P = 0.012). The treatment did not significantly modify IBS biological profile, including mast cell count. Compared with placebo, palmithoylethanolamide/polydatin markedly improved abdominal pain severity (P < 0.05). CONCLUSIONS: The marked effect of the dietary supplement palmithoylethanolamide/polydatin on abdominal pain in patients with IBS suggests that this is a promising natural approach for pain management in this condition. Further studies are now required to elucidate the mechanism of action of palmithoylethanolamide/polydatin in IBS. ClinicalTrials.gov number, NCT01370720.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Cremon C, Stanghellini V, Barbaro MR, et al. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther. 2017. PMID: 28164346. doi:10.1111/apt.13958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。